Hypertension Pulmonary Secondary Heart Failure

Cardiovascular
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Tenax Therapeutics
Tenax TherapeuticsCHAPEL HILL, NC
1 program
1
Levosimendan 2.5 mg/ml Injectable SolutionPhase 21 trial
Active Trials
NCT03624010CompletedEst. Feb 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Tenax TherapeuticsLevosimendan 2.5 mg/ml Injectable Solution

Clinical Trials (1)

NCT03624010Tenax TherapeuticsLevosimendan 2.5 mg/ml Injectable Solution

Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients

Start: Nov 2018Est. completion: Feb 2024
Phase 2Completed

Related Jobs in Cardiovascular

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space